Prometic’s Q1s showed a continued trend in reduced losses and cash burn following on from the 33% reduction in operational cash burn achieved in FY2018 (vs. a target of 10 to 15%). Speciality plasma sales and increased bioseparations volumes drove revenue growth of over 100% to $8.2m. Net losses were down 16.8% largely as a function of the increase in revenue from sales of goods of $4.0m, the decrease in R&D of $3.2m and the increase in the gain of foreign exchange of $2.9m. This wa
